BioMarker Strategies Wins NCI Grant for Biomarker System

The company plans to use the $1 million Phase II funding this year, and another $1 million in 2011, to continue developing its SnapPath live tumor cell testing system.

Full-text access for registered users only. Existing users login here.
New to GenomeWeb? Register here quickly for free access.

Related Stories